AGP Picks
View all

Feiba NF market report points to growth as hemophilia care expands

Nov. 4, 2026
Feiba NF market report points to growth as hemophilia care expands
By AI, Created 14:00 UTC, Nov 04, 2026, AGP -

The Business Research Company says the Feiba NF market is positioned for growth through 2035 as hemophilia diagnosis rates rise, home infusion expands and inhibitor screening improves. North America led the market in 2025, while the report highlights new forecasting tools and regional opportunity across global hemophilia care.

Why it matters: - Feiba NF is used to treat bleeding in hemophilia patients who have inhibitors, so demand rises when diagnosis improves and care programs expand. - The market’s growth tracks a larger shift toward home-based treatment, prophylactic care and tighter coagulation monitoring. - The report frames Feiba NF as part of a wider set of bypassing agents that remain important in inhibitor management.

What happened: - The Business Research Company released a market report on Feiba NF covering market size, trends and a global forecast for 2026-2035. - The report says the Feiba NF market is evolving as new advancements and growing awareness reshape treatment for hemophilia patients with inhibitors. - The report projects notable growth by 2026, driven by rising diagnosis rates and improved care programs. - The release includes links for a free sample of the report and the full market report.

The details: - FEIBA NF, or Factor VIII Inhibitor Bypassing Activity, is a plasma-derived therapy used for hemophilia patients who have developed inhibitors against factors VIII or IX. - The treatment contains coagulation components that bypass those inhibitors and support clotting. - FEIBA NF is used for bleeding episodes and during surgical procedures. - Safety monitoring remains important because of thromboembolic risk. - Historical growth was driven by inhibitor presence in hemophilia patients, limited treatment options, reliance on early plasma-derived therapies, hospital-based bleeding management and surgical bleeding challenges. - The report says future growth will be supported by more hemophilia diagnoses, wider home infusion programs, better inhibitor screening, more comprehensive hemophilia treatment centers and improved coagulation monitoring technologies. - Anticipated trends include continued demand for bypassing agents, more focus on bleeding control in patients with inhibitors, greater use of prophylactic hemophilia care, more home-based infusion therapy and refined safety monitoring. - The report cites hemophilia prevalence data showing about 1 in 10,000 live births affected globally and about 400,000 people living with hemophilia worldwide. - Hemophilia A accounts for 80%-85% of cases and occurs in about 1 in 5,000 live male births. - Hemophilia B occurs in about 1 in 30,000 live male births. - Hemophilia C, caused by factor XI deficiency, is rarer and is reported at roughly 1 in 100,000, with a higher incidence in Ashkenazi Jewish populations. - The World Federation of Hemophilia reported in 2023 that hemophilia A prevalence was about 17.1 per 100,000 males overall and 6.0 per 100,000 for severe cases. - The same 2023 data put hemophilia B prevalence at 3.8 per 100,000 males overall and 1.1 per 100,000 for severe forms. - The report also points to higher healthcare spending as a market catalyst because bigger budgets can support access to advanced therapies like FEIBA NF. - UK healthcare spending grew 5.6% from 2022 to 2023, compared with 0.9% growth in 2022, according to the UK's Office for National Statistics. - Total UK healthcare expenditure reached about $317.63 billion (£292 billion) in 2023. - North America held the largest share of the global Feiba NF market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The report blends disease epidemiology with healthcare spending trends, signaling that market growth depends on both clinical need and system capacity. - North America’s leading share suggests mature hemophilia treatment infrastructure is still a major advantage for adoption of inhibitor-bypassing therapies. - The added forecasting tools suggest the report is aimed at buyers looking for more granular planning, not just a high-level market overview.

What's next: - The report expects continued expansion in the Feiba NF market as screening, home infusion and comprehensive care centers broaden access. - Growth will likely depend on whether healthcare systems keep funding advanced hemophilia care and whether treatment settings continue shifting away from hospital-only management. - The company is also offering expert contact points for follow-up inquiries and sales discussions.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The European Current

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The European Current

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.